Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Market Cap:148.5M; Shares Outstanding:54.2M; Short Interest: 1.14%; Q3 2019(9/30/19): Cash 79.61M. Loss 13.79M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
|Date||Sales||% last year||% last quarter|
Total institutions: 66，no change
Shares hold: 27345.1k shares. no change
shares% hold: 50.45%，no change